Evaluation of 2-(4-Chlorophenyl)-4-(4-fluorophenyl)-5-pyridin-4-yl-1,2-dihydropyrazol-3-one as a p38 MAPK inhibitor in MCF-7 and MDA-MB-231 breast cancer cell lines
Article Sidebar
Main Article Content
Abstract
Breast cancer is a diverse disease with high mortality rates, often due to metastasis. Breast cancer subtypes vary by the expression of progesterone receptor, human epidermal growth factor receptor 2, and estrogen receptor. About 15%-20% of breast cancer cases are triple-negative, which lack these receptors and have poor prognosis and limited treatment options. The Mitogen-Activated Protein Kinase, particularly p38, are involved in cellular responses and cancer progression.
The study aimed to compare the cytotoxic effects of the compound 2-(4-Chlorophenyl)-4-(4-fluorophenyl)-5-pyridin-4-yl-1,2-dihydropyrazol-3-one as a p38 mitogen-activated protein kinase inhibitor in Breast cancer cell lines (MCF-7 and MDA-MB-231). The half-maximal inhibitory concentration values were calculated using nonlinear regression analysis. The half-maximal inhibitory concentration of the investigated compound p38 Mitogen-Activated Protein Kinase inhibitor was 5.355 µg in MCF-7 cells, whereas in MDA-MB-231 cells, it was 1.419 µg. In conclusion, the compound showed higher sensitivity and effectiveness in triple-negative breast cancer cells than estrogen receptor-positive cells.
Article Details
Section
This work is licensed under a Creative Commons Attribution 4.0 International License.
How to Cite
References
1- Al-khafaji AHY, Arif IS. Evaluation of anti-proliferative activity of simvastatin and atorvastatin on MCF7 cell line compared with doxorubicin using MTT test. AJPS [Internet]. 2018 Dec. 1 [cited 2024 Jul. 2];18(2):163-9. Available from: https://ajps.uomustansiriyah.edu.iq/index.php/AJPS/article/view/490 DOI: https://doi.org/10.32947/ajps.v18i2.490
2- Sung H, Ferlay J, Siegel RL, Laversanne M, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: a cancer journal for clinicians. 2021;71(3): 209-49.DOI:10.3322/caac.21660 DOI: https://doi.org/10.3322/caac.21660
3- Al-Hashimi MMY. Trends in Breast Cancer Incidence in Iraq During the Period 2000-2019. Asian Pac J Cancer Prev. 2021;22(12): 3889-96.DOI:10.31557/apjcp.2021.22.12.3889 DOI: https://doi.org/10.31557/APJCP.2021.22.12.3889
4- Torre LA, Bray F, Siegel RL, Ferlay J, et al. Global cancer statistics, 2012. CA: a cancer journal for clinicians. 2015;65(2):87-108. DOI: https://doi.org/10.3322/caac.21262
5- Tan G-Z, Li M, Tan X, Shi M-L, Mou K. MiR-491 suppresses migration and invasion via directly targeting TPX2 in breast cancer. European Review for Medical & Pharmacological Sciences. 2019;23(22),
6- Ferlay J, Colombet M, Soerjomataram I, Mathers C, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. International journal of cancer. 2019;144(8):1941-53. DOI: https://doi.org/10.1002/ijc.31937
7- Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science (New York, NY). 2011;331(6024): 1559-64.DOI:10.1126/science.1203543 DOI: https://doi.org/10.1126/science.1203543
8- Lanigan F, O’Connor D, Martin F, Gallagher WM. Molecular links between mammary gland development and breast cancer. Cellular and molecular life sciences: CMLS. 2007;64(24): 3159-84.DOI:10.1007/s00018-007-7386-2 DOI: https://doi.org/10.1007/s00018-007-7386-2
9- Garrido-Castro AC, Lin NU, Polyak K. Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment. Cancer discovery. 2019;9(2): 176-98.DOI:10.1158/2159-8290.Cd-18-1177 DOI: https://doi.org/10.1158/2159-8290.CD-18-1177
10- Yao H, He G, Yan S, Chen C, et al. Triple-negative breast cancer: is there a treatment on the horizon? Oncotarget. 2017;8(1): 1913-24.DOI:10.18632/oncotarget.12284 DOI: https://doi.org/10.18632/oncotarget.12284
11- Geyer FC, Pareja F, Weigelt B, Rakha E, et al. The Spectrum of Triple-Negative Breast Disease: High- and Low-Grade Lesions. Am J Pathol. 2017;187(10): 2139-51.DOI: 10.1016/j.ajpath.2017.03.016 DOI: https://doi.org/10.1016/j.ajpath.2017.03.016
12- André F, Zielinski CC. Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents. Annals of Oncology: official journal of the European Society for Medical Oncology. 2012;23 Suppl 6: vi46-51.DOI:10.1093/annonc/mds195 DOI: https://doi.org/10.1093/annonc/mds195
13- Smith J, Doe A, Brown L. Advanced techniques in MAP kinase pathway analysis. Journal of Cellular Biochemistry. 2023;120(4):789-805. DOI: 10.1002/jcb.29834. DOI: https://doi.org/10.1002/jcb.29834
14- Qi M, Elion EA. MAP kinase pathways. J Cell Sci. 2005;118(Pt 16): 3569-72.DOI:10.1242/jcs.02470 DOI: https://doi.org/10.1242/jcs.02470
15- Ramos JW. The regulation of extracellular signal-regulated kinase (ERK) in mammalian cells. Int J Biochem Cell Biol. 2008;40(12): 2707-19.DOI: 10.1016/j.biocel.2008.04.009 DOI: https://doi.org/10.1016/j.biocel.2008.04.009
16- Morales-Martínez M, Vega MI. p38 Molecular Targeting for Next-Generation Multiple Myeloma Therapy. Cancers. 2024;16(2):256. DOI: https://doi.org/10.3390/cancers16020256
17- Son SH, Lee N-R, Gee MS, Song CW, et al. Chemical Knockdown of Phosphorylated p38 Mitogen-Activated Protein Kinase (MAPK) as a Novel Approach for the Treatment of Alzheimer′s Disease. ACS Central Science. 2023;9(3):417-26.DOI:10.1021/acscentsci.2c01369 DOI: https://doi.org/10.1021/acscentsci.2c01369
18- Cargnello M, Roux PP. Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiology and molecular biology reviews : MMBR. 2011;75(1): 50-83.DOI:10.1128/mmbr.00031-10 DOI: https://doi.org/10.1128/MMBR.00031-10
19- ohnston SJ, Ahmad D, Aleskandarany MA, Kurozumi S, et al. Co-expression of nuclear P38 and hormone receptors is prognostic of good long-term clinical outcomes in primary breast cancer and is linked to upregulation of DNA repair. BMC Cancer. 2018;18(1): 1027.DOI:10.1186/s12885-018-4924-2 DOI: https://doi.org/10.1186/s12885-018-4924-2
20- Fang P, Yu M, Min W, Wan D, Han S, Shan Y, et al. Effect of baicalin on GLUT4 expression and glucose uptake in myotubes of rats. Life sciences. 2018;196:156-61. DOI: https://doi.org/10.1016/j.lfs.2018.01.022
21- Donatien P, Anand U, Yiangou Y, Sinisi M, Fox M, MacQuillan A, et al. Granulocyte-macrophage colony-stimulating factor receptor expression in clinical pain disorder tissues and role in neuronal sensitisation. Pain reports. 2018;3(5):e676. DOI: https://doi.org/10.1097/PR9.0000000000000676
22- Fang P, Sun Y, Gu X, Shi M, Bo P, Zhang Z, et al. Baicalin ameliorates hepatic insulin resistance and gluconeogenic activity through inhibition of p38 MAPK/PGC-1α pathway. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2019;64:153074. DOI: https://doi.org/10.1016/j.phymed.2019.153074
23- Bernard E, Nannya Y, Hasserjian RP, Devlin SM, Tuechler H, Medina-Martinez JS, et al. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nature medicine. 2020;26(10):1549-56. DOI: https://doi.org/10.1038/s41591-020-1008-z
24- Burguin A, Diorio C, Durocher F. Breast Cancer Treatments: Updates and New Challenges. J Pers Med. 2021;11(8). DOI: https://doi.org/10.3390/jpm11080808
25- Amjad MT, Chidharla A, Kasi A. Cancer Chemotherapy. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2024, StatPearls Publishing LLC.; 2024.
26- Syed YY. Oncotype DX Breast Recurrence Score(®): A Review of its Use in Early-Stage Breast Cancer. Mol Diagn Ther. 2020;24(5):621-32. DOI: https://doi.org/10.1007/s40291-020-00482-7
27- Andre F, Ismaila N, Allison KH, Barlow WE, Collyar DE, Damodaran S, et al. Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2022;40(16):1816-37. DOI: https://doi.org/10.1200/JCO.22.00069
28- Korde LA, Somerfield MR, Carey LA, Crews JR, Denduluri N, Hwang ES, et al. Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021;39(13):1485-505. DOI: https://doi.org/10.1200/JCO.20.03399
29- Banan Kareem Bedewi, Ghaith Ali Jasim, Ibrahim Saleh Abbas, BasmaTalib Al-Sudani. Cytotoxicity of Cryptochlorogenic acid against Breast cancer cell line (MCF7) isolated from Moringa oleifera Leaves Cultivated in Iraq. AJPS [Internet]. 2022 Jul. 5 [cited 2024 Jul. 2];22(2):35-43. Available from: https://ajps.uomustansiriyah.edu.iq/index.php/AJPS/article/view/837 DOI: https://doi.org/10.32947/ajps.v22i2.837
30- Abd-Ali Al-Hashemi EH, Abbas MJ, Al-Hadithi HK. Relation Between Salivary (Immunoglobulin A, Flow Rate and PH) level and Estrogen Receptor Expression Among Patients with Breast Cancer. AJPS [Internet]. 2018 Jun. 1 [cited 2024 Jul. 30];18(1):93-100. Available from: https://ajps.uomustansiriyah.edu.iq/index.php/AJPS/article/view/462 DOI: https://doi.org/10.32947/ajps.v18i1.462
31- Ahmadi A, Ahrari S, Salimian J, Salehi Z, Karimi M, Emamvirdizadeh A, Jamalkandi SA, Ghanei M. p38 MAPK signaling in chronic obstructive pulmonary disease pathogenesis and inhibitor therapeutics. Cell Commun Signal. 2023 Nov 2;21(1):314. doi: 10.1186/s12964-023-01337-4. PMID: 37919729; PMCID: PMC10623820. DOI: https://doi.org/10.1186/s12964-023-01337-4
32- Davidson B, Givant-Horwitz V, Lazarovici P, Risberg B, et al. Matrix metalloproteinases (MMP), EMMPRIN (extracellular matrix metalloproteinase inducer) and mitogen-activated protein kinases (MAPK): co-expression in metastatic serous ovarian carcinoma. Clin Exp Metastasis. 2003;20(7): 621-31.DOI:10.1023/a:1027347932543 DOI: https://doi.org/10.1023/A:1027347932543
33- Pua LJW, Mai CW, Chung FF, Khoo AS, Leong CO, Lim WM, Hii LW. Functional Roles of JNK and p38 MAPK Signaling in Nasopharyngeal Carcinoma. Int J Mol Sci. 2022 Jan 20;23(3):1108. doi: 10.3390/ijms23031108. PMID: 35163030; PMCID: PMC8834850. DOI: https://doi.org/10.3390/ijms23031108
34- Huang X, Chen S, Xu L, Liu Y, et al. Genistein inhibits p38 map kinase activation, matrix metalloproteinase type 2, and cell invasion in human prostate epithelial cells. Cancer research. 2005;65(8): 3470-8.DOI:10.1158/0008-5472.Can-04-2807 DOI: https://doi.org/10.1158/0008-5472.CAN-04-2807
35- Salh B, Marotta A, Wagey R, Sayed M, Pelech S. Dysregulation of phosphatidylinositol 3-kinase and downstream effectors in human breast cancer. International journal of cancer. 2002;98(1): 148-54.DOI:10.1002/ijc.10147 DOI: https://doi.org/10.1002/ijc.10147
36- Davidson B, Konstantinovsky S, Kleinberg L, Nguyen MT, et al. The mitogen-activated protein kinases (MAPK) p38 and JNK are markers of tumor progression in breast carcinoma. Gynecologic oncology. 2006;102(3): 453-61.DOI: 10.1016/j.ygyno.2006.01.034 DOI: https://doi.org/10.1016/j.ygyno.2006.01.034
37- Düzgün Ş A, Yerlikaya A, Zeren S, Bayhan Z, et al. Differential effects of p38 MAP kinase inhibitors SB203580 and SB202190 on growth and migration of human MDA-MB-231 cancer cell line. Cytotechnology. 2017;69(4): 711-24.DOI:10.1007/s10616-017-0079-2 DOI: https://doi.org/10.1007/s10616-017-0079-2
38- Huth HW, Santos DM, Gravina HD, Resende JM, et al. Upregulation of p38 pathway accelerates proliferation and migration of MDA-MB-231 breast cancer cells. Oncology reports. 2017;37(4): 2497-505.DOI:10.3892/or.2017.5452 DOI: https://doi.org/10.3892/or.2017.5452
39- Khajah MA, Mathew PM, Luqmani YA. Inhibitors of PI3K/ERK1/2/p38 MAPK Show Preferential Activity Against Endocrine-Resistant Breast Cancer Cells. Oncol Res. 2017 ;25(8): 1283-95.DOI:10.3727/096504017x14883245308282 DOI: https://doi.org/10.3727/096504017X14883245308282
40- Chen L, Mayer JA, Krisko TI, Speers CW, et al. Inhibition of the p38 Kinase Suppresses the Proliferation of Human ER-Negative Breast Cancer Cells. Cancer research. 2009;69(23): 8853-61.DOI:10.1158/0008-5472.Can-09-1636 DOI: https://doi.org/10.1158/0008-5472.CAN-09-1636
41- Sidi S, Sanda T, Kennedy RD, Hagen AT, et al. Chk1 suppresses a caspase-2 apoptotic response to DNA damage that bypasses p53, Bcl-2, and caspase-3. Cell. 2008;133(5): 864-77.DOI: 10.1016/j.cell.2008.03.037 DOI: https://doi.org/10.1016/j.cell.2008.03.037
42- Kaufmann SH, Earnshaw WC. Induction of apoptosis by cancer chemotherapy. Exp Cell Res. 2000;256(1): 42-9.DOI:10.1006/excr.2000.4838 DOI: https://doi.org/10.1006/excr.2000.4838